BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25630534)

  • 1. Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.
    Lai H; Zhao Z; Li L; Zheng W; Chen T
    Metallomics; 2015 Mar; 7(3):439-47. PubMed ID: 25630534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
    J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.
    Yang L; Zhang J; Wang C; Qin X; Yu Q; Zhou Y; Liu J
    Metallomics; 2014 Mar; 6(3):518-31. PubMed ID: 24336978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
    Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
    Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ.
    Park JH; Lee KS; Lim HJ; Kim H; Kwak HJ; Park HY
    J Cell Biochem; 2012 Jun; 113(6):1947-54. PubMed ID: 22234939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
    J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
    Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
    Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.
    Kwong WL; Lam KY; Lok CN; Lai YT; Lee PY; Che CM
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13524-13528. PubMed ID: 27717148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest.
    Ling Y; Chen Y; Chen P; Hui H; Song X; Lu Z; Li C; Lu N; Guo Q
    Exp Biol Med (Maywood); 2011 Jul; 236(7):851-8. PubMed ID: 21659383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M; Wu S; Liu Z; Zhang W; Xu J; Wang Y; Liu J; Zhang D; Tian H; Li Y; Ye W
    Biochem Pharmacol; 2012 May; 83(9):1251-60. PubMed ID: 22305746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers.
    Nagababu P; Barui AK; Thulasiram B; Devi CS; Satyanarayana S; Patra CR; Sreedhar B
    J Med Chem; 2015 Jul; 58(13):5226-41. PubMed ID: 26068145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Design of Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing p53 Activation.
    Deng Z; Yu L; Cao W; Zheng W; Chen T
    ChemMedChem; 2015 Jun; 10(6):991-8. PubMed ID: 25914192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palladium (II) complex and thalidomide intercept angiogenic signaling via targeting FAK/Src and Erk/Akt/PLCγ dependent autophagy pathways in human umbilical vein endothelial cells.
    Aydinlik S; Uvez A; Kiyan HT; Gurel-Gurevin E; Yilmaz VT; Ulukaya E; Armutak EI
    Microvasc Res; 2021 Nov; 138():104229. PubMed ID: 34339726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.
    Mazuryk O; Suzenet F; Kieda C; Brindell M
    Metallomics; 2015 Mar; 7(3):553-66. PubMed ID: 25711770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deltonin inhibits angiogenesis by regulating VEGFR2 and subsequent signaling pathways in endothelial cells.
    Tong Q; Zhao Q; Qing Y; Hu X; Jiang L; Wu X
    Steroids; 2015 Apr; 96():30-6. PubMed ID: 25554580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
    Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.